Rizhao completes the first double autologous hematopoietic stem cell transplantation

"Congratulations to the warehouse!" On June 27, the patients with multiple osteoma, the 53 -year -old Mr. Liu, returned to normal for the second time of autologous hematopoietic stem cell transplantation. This is the first double autologous hematopoietic stem cell transplantation for the successful completion of the blood department of the Municipal People's Hospital for the treatment of multiple osteoma.

In July 2021, Mr. Liu was in difficulty in ribs and waist pain. In January, he stayed at the Department of Blood Medicine of the Municipal People's Hospital. The imaging examination prompted multiple skeletal destruction of the whole body. After examinations such as molecular biology, it is found that patients have complex chromosomal nucleus type and No. 1 chromosome amplification, which belongs to a typical high -risk multi -type osteoma.

Mr. Liu is a sports enthusiast and is usually strong. However, due to the torture of the disease, low back pain and rib pain when admitting are serious, difficult to turn over, and cannot breathe smoothly.

After communicating with the patient and his family members and his family members, Liu Jiaqiang, deputy director of the Department of Hematology, formulated a comprehensive and detailed diagnosis and treatment plan for Mr. Liu. The standard scheme chemotherapy was performed first. After two cycles, the pain improved significantly. It was free to move down the ground. The mood improved. After the four cycles, the effect was obvious. It reached the standard of autologous bone marrow transplantation. After repeated discussions by Liu Caqiang's team, patients can perform double autologous hematopoietic stem cell transplantation.

Double autologous hematopoietic stem cell transplantation, also known as series transplantation, refers to the second autologous hematopoietic stem cell transplantation in the plan within 6 months after the first autologous hematopoietic stem cell transplantation. It is also a treatment method for priority recommended by major clinical guidelines.

However, due to the lack of number of autologous hematopoietic stem cells, age factors, patient physical fitness, large -doses of chemotherapy side effects, high risk of transplantation process, less than 20%of patients who can do bone marrow transplantation in my country. There are very few patients. According to incomplete statistics, only 4 patients with myeloma in Shandong have completed double transplants last year.

Beginning in January 2022, mobilized stem cells for the patients, and under the close cooperation of blood transfusion, radiotherapy and other departments, collected sufficient double transplants stem cells, and gave a large dose of US Fulun pre -treatment on February 25th and 26th. On February 28, the first retreat from autologous stem cells, the patient successfully spent the adverse reaction period such as nausea, vomiting, diarrhea, rash, and bone marrow suppression. The hematopoietic function gradually recovered and was discharged smoothly on March 14.

After the patient's transplantation, the patient was recovered well, the clinical symptoms disappeared, and the body could improve. After 1 month, the bone marrow was reviewed. It was found that the number of chromosomal dysfunction was completely disappeared. In order to further consolidate the efficacy, a second transplant was admitted to the hospital on June 4. Full preparations during the two transplants, and various protection in place. Patients have not experienced severe infection, bleeding and other complications.

"Compared to the transplantation of hematopoietic stem cells that comes from other people, the advantages of autologous hematopoietic stem cell transplantation are obvious." Deputy Director Liu Qianqiang said that hematopoietic stem cells are derived from the patient themselves, and there will be no transplant exclusion. The overall cost is less.

The success of the first double autologous hematopoietic stem cell transplantation fully demonstrates that the blood internal transplantation team is gradually linked to the domestic and international advanced osteomyoma diagnosis and treatment centers. It is understood that the team plans to complete 3 dual autologous hematopoietic stem cell transplants in the second half of the year. At present, the work of collecting double transplants stem cells has been successfully completed. This technology has filled the city's high -risk multi -occurrence bone marrow tumor double autologous hematopoietic stem cells The gap of transplantation. (Rizhao Newspaper All -Media Reporter Sui Yanchen Teng Weiwei Correspondent Zhao Jingwen Jing Jing report)

- END -